Mylan, Cipla, Ferozsons Laboratories, Hetero Labs and Jubilant Life Sciences will make remdesivir for distribution in countries that “face significant obstacles to healthcare access,” Gilead said.
The deal will be royalty-free until the World Health Organization says COVID-19 is no longer a global health crisis or another pharmaceutical product besides remdesivir or a vaccine is approved to treat or prevent COVID-19.
Remdesivir was granted emergency use authorization by the FDA May 1 after it was shown to shorten the recovery time of some COVID-19 patients in preliminary studies.
Read the full news release here.
More articles on pharmacy:
HHS unveils plan to distribute Gilead’s COVID-19 drug
Two-thirds of hospital pharmacies have reduced staff during COVID-19 pandemic, ASHP survey finds
New CMS rule could raise out-of-pocket drug costs
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
